Your browser doesn't support javascript.
loading
Vaginal compared with intramuscular progestogen for preventing preterm birth in high-risk pregnant women (VICTORIA study): a multicentre, open-label randomised trial and meta-analysis.
Choi, S-J; Kwak, D W; Kil, K; Kim, S-C; Kwon, J-Y; Kim, Y H; Na, S; Bae, J-G; Cha, H-H; Shim, J-Y; Oh, K Y; Lee, K A; Kim, S M; Cho, I A; Lee, S M; Cho, G J; Jo, Y S; Choi, G Y; Choi, S K; Hur, S E; Hwang, H S; Kim, Y J.
Afiliação
  • Choi SJ; Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Kwak DW; Ajou University School of Medicine, Suwon, Korea.
  • Kil K; Yeouido St Mary's Hospital, The Catholic University of Korea, Seoul, Korea.
  • Kim SC; Pusan National University College of Medicine, Pusan, Korea.
  • Kwon JY; Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.
  • Kim YH; Chonnam National University Medical School, Gwangju, Korea.
  • Na S; Kangwon National University Hospital, School of Medicine Kangwon National University, Chuncheon, Korea.
  • Bae JG; Keimyung University School of Medicine, Daegu, Korea.
  • Cha HH; Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea.
  • Shim JY; Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Oh KY; School of Medicine, Eulji University, Daejeon, Korea.
  • Lee KA; Kyung Hee University School of Medicine, Seoul, Korea.
  • Kim SM; Seoul Metropolitan Government Seoul National University Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
  • Cho IA; Gyeongsang National University Hospital, Gyeongsang National University School of Medicine, Jinju, Korea.
  • Lee SM; Seoul National University College of Medicine, Seoul, Korea.
  • Cho GJ; Korea University College of Medicine, Seoul, Korea.
  • Jo YS; St Vincent's Hospital, College of Medicine, The Catholic University of Korea, Suwon, Korea.
  • Choi GY; Soonchunhyang University Seoul Hospital, College of Medicine, Soonchunhyang University, Seoul, Korea.
  • Choi SK; College of Medicine, The Catholic University of Korea, Seoul, Korea.
  • Hur SE; Konyang University Hospital, Daejeon, Korea.
  • Hwang HS; Research Institute of Medical Science, Konkuk University School of Medicine, Seoul, Korea.
  • Kim YJ; College of Medicine, Ewha Womans University, Seoul, Korea.
BJOG ; 127(13): 1646-1654, 2020 12.
Article em En | MEDLINE | ID: mdl-32536019
ABSTRACT

OBJECTIVE:

To compare the efficacy of two types of progestogen therapy for preventing preterm birth (PTB) and to review the relevant literature.

DESIGN:

A multicentre, randomised, open-label, equivalence trial and a meta-analysis.

SETTING:

Tertiary referral hospitals in South Korea. POPULATION Pregnant women with a history of spontaneous PTB or short cervical length (<25 mm).

METHODS:

Eligible women were screened and randomised at 16-22 weeks of gestation to receive either 200 mg of vaginal micronised progesterone daily (vaginal group) or an intramuscular injection of 250 mg 17α-hydroxyprogesterone caproate weekly (IM group). Stratified randomisation was carried out according to participating centres and indications for progestogen therapy. This trial was registered at ClinicalTrials.gov (NCT02304237). MAIN OUTCOME

MEASURE:

Preterm birth (PTB) before 37 weeks of gestation.

RESULTS:

A total of 266 women were randomly assigned and a total of 247 women (119 and 128 women in the vaginal and IM groups, respectively) were available for the intention-to-treat analysis. Risks of PTB before 37 weeks of gestation did not significantly differ between the two groups (22.7 versus 25.8%, P = 0.571). The difference in PTB risk between the two groups was 3.1% (95% CI -7.6 to 13.8%), which was within the equivalence margin of 15%. The meta-analysis results showed no significant differences in the risk of PTB between the vaginal and IM progestogen treatments.

CONCLUSION:

Compared with vaginal progesterone, treatment with intramuscular progestin might increase the risk of PTB before 37 weeks of gestation by as much as 13.8%, or reduce the risk by as much as 7.6%, in women with a history of spontaneous PTB or with short cervical length. TWEETABLE ABSTRACT Vaginal and intramuscular progestogen showed equivalent efficacy for preventing preterm birth before 37 weeks of gestation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Progestinas / Nascimento Prematuro Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: BJOG Assunto da revista: GINECOLOGIA / OBSTETRICIA Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Progestinas / Nascimento Prematuro Tipo de estudo: Clinical_trials / Etiology_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Female / Humans / Pregnancy Idioma: En Revista: BJOG Assunto da revista: GINECOLOGIA / OBSTETRICIA Ano de publicação: 2020 Tipo de documento: Article